Adenosine A(2A)R/A(1)R Antagonists Enabling Additional H(3)R Antagonism for the Treatment of Parkinson’s Disease

Adenosine A(2A)R/A(1)R Antagonists Enabling Additional H(3)R Antagonism for the Treatment of Parkinson’s Disease
J Med Chem. 2021 Jun 9. doi: 10.1021/acs.jmedchem.0c00914. Online ahead of print.ABSTRACTAdenosine A1/A2A receptors (A1R/A2AR) represent targets in nondopaminergic treatment of motor disorders such as Parkinson's disease (PD). As an innovative strategy, multitargeting ligands (MTLs) were developed to achieve comprehensive PD therapies simultaneously addressing comorbid symptoms such as sleep disruption. Recognizing the wake-promoting capacity of histamine H3 receptor (H3R) antagonists ... read more
Source: PubMedPublished on 2021-06-09By Stefanie Hagenow